Search

INTRODUCTION AND OBJECTIVE:Advances in artificial intelligence (AI) techniques have allowed for the development of prognostic models using digital images of pathology slides. In this study we use d...

INTRODUCTION AND OBJECTIVES:Malignant pheochromocytomas (MP) are a rare form of endocrine malignancy which can occur in familial and sporadic clinical settings. We performed comprehensive genomic p...

INTRODUCTION AND OBJECTIVES:Relapsed and metastatic penile (mPSCC) and uterine cervical squamous cell carcinoma (mCSCC) are aggressive forms of malignancy with currently limited systemic treatment ...

INTRODUCTION AND OBJECTIVES: Cisplatin is one of the most widely used and highly effective drug for the treatment of various solid tumors including germ cell tumors (GCTs). However, it has dosedependent side effects and among them, nephrotoxicity is the most well-known and clinically important toxicity. Nedaplatin is a secondgeneration platinum complex with reduced nephrotoxicity that exerts its antitumor activity against various cancers. Based on our previous report (Int J Clin Oncol 2009;14:436), nedaplatin exerted the equivalent antitumor effect as cisplatin with less toxicity in patients with relapsed or refractory GCTs. In this study, we investigated the efficacy and safety of a regimen consisting of paclitaxel and ifosfamide plus nedaplatin (TIN) for refractory or relapsed GCTs in patients with impaired renal function. METHODS: Among 68 patients who underwent TIN chemotherapy for refractory or relapsed GCTs, ten patients with study entry criterion of eGFR (estimated glemerular filtration rate) < 60 ml/min/ 1.73m were assessed. The combination chemotherapy consisted of paclitaxel (210 mg/m) on day 1 and ifosfamide (1.2 g/m) on days 2-6 in combination with nedaplatin (100 mg/m) on day 2 every 3 weeks. RESULTS: Patients enrolled in this study exhibited eGFR with a median of 49.97 mg/ml/1.73m (range 31.7-57.5). Paclitaxel, ifosfamide and nedaplatin therapy was carried out as second-line therapy in 4 patients, third-line in 4 and fourth-line or later in 2. Patients were pretreated with a median of 5.5 cycles of platinum-based chemotherapy (range 3-11 cycles) and administered with a median of 550mg/m2 of cisplatin. Patients received 2-6 cycles of the TIN combination chemotherapy and the overall response rate was 90%. No patient with chemotherapy-induced kidney dysfunction was observed. Furthermore, among the patients undergoing TIN therapy, there was no difference in the frequency of side effects between eGFR ?60 ml/min/1.73 m and eGFR

INTRODUCTION AND OBJECTIVES: Bladder cancer (BCa), may present with variant morphologic features that deviate from the urothelial common aspect. These characteristics that can be defined as pure or mixed variants may have prognostic and therapeutic implications. METHODS: We retrospectively evaluated histopathological data from 1,067 BCa patients treated with radical cystectomy (RC) and PLND for BCa between 1990 and 2013 at a single tertiary care referral center. All specimen were evaluated by dedicated uropathologists. Uniand multivariate Cox regression analyses tested the impact of different histopathological variant CSM (cancer specific mortality) and OM (overall mortality) after accounting for age at surgery, pathological N stage, use of perioperative chemotherapy, number of positive nodes, number of removed nodes, positive surgical margin, pathological T stage, lymph vascular invasion, use of adjuvant chemotherapy. RESULTS: Of 1,067 patients, 756 (70.9%) harbored pure urothelial BCa while 311 (29.1%) were found to have a variant. Of these, 202 (64.9%) had a mixed variant and 109 (35.1%) a pure variant. Considering uncommon variants, 21 (6.8%) were sarcomatoid, 10 (3.2%) lymphoepitelial, 19 (6.1%) small cell, 4 (1.3%) plasmacitoid, 2 (0.6%) nested, 109 (35.0%) squamous, 89 (28.6%) micropapillary, 23 (7.4%) glandular and 34 (10.9%) multiple mixed. With a median follow up of 65 months, CSM and OM were recorded in 365 (34.2%), 451 (42.3%) patients, respectively. The OM was 47% vs. 53% vs. 59% for pure urothelial vs. mixed vs. pure variants, respectively (Log rank p1⁄40.011). The 5-years CSM was 44% vs. 47% vs. 53% for pure urothelial vs. mixed vs. pure variants, respectively (Log rank p1⁄40.019). At MVA Cox regression analyses, the presence of pure histological variant was associated with higher CSM (HR: 1.60, p 0.3). In details, neuroendocrine (HR 4.30, CI 2.02-9.13, p